Two tests. Two different questions.
Sterility testing looks for viable microorganisms under defined test conditions. Bacterial endotoxin testing measures a different form of contamination. One result cannot stand in for the other, and neither can be inferred from a chromatographic purity percentage.
Start with the original laboratory report. Its sample identification, method, result and limitations determine what the evidence supports. This guide explains the terminology; it does not establish which tests were performed on any catalog material.
Match the method to the question
| Test family | What it examines | What it does not establish |
|---|---|---|
| Microbial enumeration USP <61> | Counts of bacteria and fungi recoverable under the stated conditions. | A sterility conclusion or an endotoxin result. |
| Specified microorganisms USP <62> | The organisms specifically named within the testing scope. | Absence of every possible microorganism. |
| Sterility USP <71> | Evidence of microbial growth in the tested sample under the specified conditions. | A guarantee for every untested container or future handling. |
| Bacterial endotoxins USP <85> or <86> | Endotoxin detection or measurement using the reported assay. | A count of living organisms or a sterility conclusion. |
USP describes these as separate methods: microbial enumeration, specified microorganisms, sterility and recombinant endotoxin assays.
Membrane filtration and direct inoculation
These are two approaches to a growth-based sterility test. The distinction is how the sample is presented to the culture medium, rather than two different definitions of sterility.
| Approach | General principle | What matters when reading the report |
|---|---|---|
| Membrane filtration | Microorganisms are retained on a membrane, which is then assessed for growth in suitable culture media. | Whether the material is filterable and whether the method demonstrates recovery in the presence of sample residues. |
| Direct inoculation | A portion of the sample is placed directly into culture medium and examined for growth. | Whether components of the sample interfere with microbial recovery or obscure the observation. |
USP <71> uses membrane filtration where the nature of the material permits, with direct inoculation as another described approach. The laboratory must justify and establish suitability for its chosen method. See USP's published sterility-method reference; the applicable current chapter and the laboratory's procedure govern the actual test.
Why method suitability belongs beside the result
The method must be capable of recovering microorganisms in the presence of the material being examined. For example, an inhibitory sample can prevent growth even when the culture medium itself performs correctly. A growth-promotion check of the medium and a suitability assessment with the sample answer related but different questions.
Ask whether the report or supporting method documentation addresses sample interference, microbial recovery, positive controls and negative controls. A clear-looking culture alone does not resolve these questions. USP's microbial recovery guidance explains why a recognized compendial method still needs demonstrated suitability for the specific material.
How to read a sterility result
A report should identify the sample, the test method and the laboratory's conclusion. Read that conclusion within its stated scope. The ability to recover microorganisms from the particular sample matters, so ask whether method suitability and relevant controls were satisfactory.
A negative result is evidence about the material sampled and the conditions used. It does not measure contamination that the method cannot recover, or establish what happens to a container after testing. FDA's discussion of sterility-test limitations explains why sampling, microbial growth conditions and container integrity are separate considerations.
Gel-clot, turbidimetric and chromogenic assays
Traditional bacterial endotoxin assays use a lysate reagent, often called LAL. The method name identifies how its reaction is observed.
| Assay | Signal observed | Report distinction |
|---|---|---|
| Gel-clot | Formation of a firm gel in the assay. | Often reported as a qualitative limit result; the report should identify the sensitivity and sample basis. |
| Turbidimetric | A change in cloudiness measured optically. | Can use an endpoint or a kinetic measurement. Read the result with its calibration and reporting limit. |
| Chromogenic | A color change produced by the assay reaction. | Can use an endpoint or a kinetic measurement. The sample must not compromise the optical or biochemical readout. |
Endpoint describes a reading at a defined endpoint; kinetic describes monitoring the developing signal over time. Neither label alone says whether an assay is suitable for the sample. FDA's microbiology manual, bacterial endotoxin testing chapter describes these readout families.
Recombinant reagents: rFC and recombinant cascade
USP <86> describes additional assays using nonanimal-derived recombinant reagents. Recombinant Factor C (rFC) uses the endotoxin-responsive Factor C protein. Recombinant cascade reagents (rCR) include recombinant Factor C, Factor B and proclotting enzyme. These describe the reagent system; the original report should also identify the detection method.
Recombinant testing does not make the sample-interference question disappear. Look for the assay's suitability evidence rather than assuming that one reagent family performs identically in every material. USP <86> adds alternatives to <85>, with applicability depending on the relevant requirements. FDA's recombinant-reagent update likewise emphasizes suitability for the particular material.
How to read an endotoxin result
Keep the numerical result, unit and reporting limit together. A result stated as less than the reporting limit means the assay did not quantify a value above that limit. It does not mean an absolute zero.
Ask which assay was used and whether the sample affected its performance. A matrix can interfere with a measurement, so the laboratory's suitability assessment is part of interpreting the result. Acceptance criteria must be identified for the particular evaluation; this guide supplies no universal cutoff.
Interference can suppress or enhance the assay signal. Ask whether suitable positive sample controls and other checks supported the reported interpretation. A method name without that context is an incomplete description of the evidence.
Five checks before relying on a report
- Match the sample. Confirm the material, size, lot and report reference.
- Name the test. Distinguish sterility, microbial counts, specified organisms and endotoxins.
- Read the result precisely. Keep units, reporting limits and acceptance criteria attached.
- Check the method's scope. Look for suitability, controls, qualifications and any stated deviations.
- Identify what is missing. An omitted test is unreported, not a passing result.
Find the tests actually reported in the batch certificate library. For more context, read how to read a COA or the USP testing-method chapter guide.
Keep method education separate from product claims
A USP chapter reference is not evidence that Next Era Peptide or its laboratory performed that method, and it is not a USP certification. The original report establishes the testing scope. These references explain analytical concepts; they do not establish approval or suitability for human or veterinary use.
For the underlying framework, see FDA's endotoxin testing guidance. It concerns regulated products and should not be treated as approval of research materials.